|
|
 |
|
Viewing report
|
|
|
|
Cough, Cold and Allergy (Hay Fever) Remedies in New Zealand
Euromonitor International, March 2012, Pages: 34
During 2010, the Associate Minister of Health introduced the Misuse of Drugs Amendment Bill which reclassified pseudoephedrine and ephedrine as Class B2 controlled drugs. This followed an agreement by the cabinet in September 2009 to reclassify these two drugs considering the fact they are active ingredients used in the manufacture of the Class A controlled drug methamphetamine. Prior to the reclassification, pseudoephedrine was available over the counter in cold and flu remedies from...
The Cough, Cold and Allergy (Hay Fever) Remedies in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Product coverage: Antihistamines/Allergy Remedies (Systemic), Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies, Cough Remedies, Decongestants, Medicated Confectionery, Paediatric Cough, Cold and Allergy Remedies, Pharyngeal Preparations.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
|
|
|
|
